- Home
- AIRT vs COEP Comparison
AIRT vs COEP Comparison
Compare AIRT & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- COEP
- Stock Information
- Founded
- AIRT 1980
- COEP 2017
- Country
- AIRT United States
- COEP United States
- Employees
- AIRT N/A
- COEP N/A
- Industry
- AIRT Air Freight/Delivery Services
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRT Consumer Discretionary
- COEP Health Care
- Exchange
- AIRT Nasdaq
- COEP Nasdaq
- Market Cap
- AIRT 59.6M
- COEP 62.4M
- IPO Year
- AIRT N/A
- COEP N/A
- Fundamental
- Price
- AIRT $24.46
- COEP $12.60
- Analyst Decision
- AIRT
- COEP
- Analyst Count
- AIRT 0
- COEP 0
- Target Price
- AIRT N/A
- COEP N/A
- AVG Volume (30 Days)
- AIRT 1.2K
- COEP 39.1K
- Earning Date
- AIRT 11-11-2025
- COEP 11-12-2025
- Dividend Yield
- AIRT N/A
- COEP N/A
- EPS Growth
- AIRT N/A
- COEP N/A
- EPS
- AIRT N/A
- COEP N/A
- Revenue
- AIRT $296,309,000.00
- COEP $263,555.00
- Revenue This Year
- AIRT N/A
- COEP N/A
- Revenue Next Year
- AIRT N/A
- COEP N/A
- P/E Ratio
- AIRT N/A
- COEP N/A
- Revenue Growth
- AIRT 5.14
- COEP N/A
- 52 Week Low
- AIRT $14.56
- COEP $2.31
- 52 Week High
- AIRT $26.70
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- AIRT 55.22
- COEP 51.40
- Support Level
- AIRT $22.63
- COEP $12.09
- Resistance Level
- AIRT $26.37
- COEP $13.25
- Average True Range (ATR)
- AIRT 0.33
- COEP 0.73
- MACD
- AIRT 0.12
- COEP -0.12
- Stochastic Oscillator
- AIRT 53.53
- COEP 45.78
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.